Tumor metastasis and recurrence is the main concern in cancer therapy. This is frequently due to the deregulation of intracellular signaling that mediate communication nets between tumor initiating cells and the tumor microenvironment. The signaling pathways more frequently aberrantly modified in tumor progression are Wnt/ß-catenin, Notch, Hippo, MAPK, Hedgehog, JAK/STAT, NF-kB, among others. Many signaling pathways are evolutionarily conserved with physiological functions related to embryonic development, organ size, cell renewal, cell homeostasis, stress response or immunity. Nevertheless, they play important roles in tumor progression closely involved in tumor survival, angiogenesis, metastasis, as well as immune escape and immunotherapy resistance. In fact, the dysregulation of these intracellular pathways supports a global mechanism that allow tumor cells to dampen immunity and overcome a wide array of adverse conditions such as drugs or immunotherapeutic agents. These signalling pathways can act by intrinsic modification of tumor cells and/or through modulation of stromal/immune cell populations within the tumor microenvironment. Based on this premise, a multifactorial strategy targeting signalling pathways that contribute to the tumor survival and immunity may allow the identification of new therapeutic targets that could improve tumor elimination.
This Research Topic aims to provide an update of the signaling pathways as it relates to tumor survival by inducing immune escape strategies and/or development of therapy resistance mechanisms. Also, an overview of therapeutic approaches targeted to restore anti-tumoral immunity and overcome therapy resistance are accepted. Accordingly, we welcome the submission of both Review and Original Research articles related to the following topics:
1. Role of tumor cell specific signaling pathways on anti-tumoral immune response and therapy resistance.
2. Role of immune cell specific signaling pathways on anti-tumoral immune response and therapy resistance.
3. Role of stromal cell specific signaling pathways on anti-tumoral immune response and therapy resistance.
4. Interplay between signaling pathways and the consequences for immunity and resistance.
5. Combinatorial targeted therapeutic intervention based on the modulation of signaling pathways underlying the mechanisms involved in tumor immune escape and/or therapy resistance.
Dr. Brent Hanks receives research funding from Merck, D3 A*STAR Singapore, Tempest Therapeutics, Leap Therapeutics, Sanofi, and Exicure. The other Topic Editors declare no competing interests with regards to the Research Topic theme.
Tumor metastasis and recurrence is the main concern in cancer therapy. This is frequently due to the deregulation of intracellular signaling that mediate communication nets between tumor initiating cells and the tumor microenvironment. The signaling pathways more frequently aberrantly modified in tumor progression are Wnt/ß-catenin, Notch, Hippo, MAPK, Hedgehog, JAK/STAT, NF-kB, among others. Many signaling pathways are evolutionarily conserved with physiological functions related to embryonic development, organ size, cell renewal, cell homeostasis, stress response or immunity. Nevertheless, they play important roles in tumor progression closely involved in tumor survival, angiogenesis, metastasis, as well as immune escape and immunotherapy resistance. In fact, the dysregulation of these intracellular pathways supports a global mechanism that allow tumor cells to dampen immunity and overcome a wide array of adverse conditions such as drugs or immunotherapeutic agents. These signalling pathways can act by intrinsic modification of tumor cells and/or through modulation of stromal/immune cell populations within the tumor microenvironment. Based on this premise, a multifactorial strategy targeting signalling pathways that contribute to the tumor survival and immunity may allow the identification of new therapeutic targets that could improve tumor elimination.
This Research Topic aims to provide an update of the signaling pathways as it relates to tumor survival by inducing immune escape strategies and/or development of therapy resistance mechanisms. Also, an overview of therapeutic approaches targeted to restore anti-tumoral immunity and overcome therapy resistance are accepted. Accordingly, we welcome the submission of both Review and Original Research articles related to the following topics:
1. Role of tumor cell specific signaling pathways on anti-tumoral immune response and therapy resistance.
2. Role of immune cell specific signaling pathways on anti-tumoral immune response and therapy resistance.
3. Role of stromal cell specific signaling pathways on anti-tumoral immune response and therapy resistance.
4. Interplay between signaling pathways and the consequences for immunity and resistance.
5. Combinatorial targeted therapeutic intervention based on the modulation of signaling pathways underlying the mechanisms involved in tumor immune escape and/or therapy resistance.
Dr. Brent Hanks receives research funding from Merck, D3 A*STAR Singapore, Tempest Therapeutics, Leap Therapeutics, Sanofi, and Exicure. The other Topic Editors declare no competing interests with regards to the Research Topic theme.
